Navigation Links
New Handheld Base Unit for CoaguChek XS Plus System Enables Connectivity to RALS-Plus Data Management Solution for PT/INR Testing at the Point of Care

Centralized control of anticoagulation meters and data can help healthcare providers decrease costs and improve care for patients on warfarin therapy

INDIANAPOLIS, Nov. 11 /PRNewswire/ -- The U.S. Food and Drug Administration has granted approval for the new Handheld Base Unit for the CoaguChek(R) XS Plus System, which provides connectivity between the anticoagulation meter and the RALS(R)-Plus data management system and enables hospital networks to easily capture, access and manage essential patient, operator and quality data for point-of-care PT/INR (clotting time) testing.

The connectivity capability with RALS-Plus allows for network-wide data management and bi-directional data transfer with anticoagulation meters, which can help point of care (POC) coordinators and others ensure the accuracy of patient records and improve the safety of patients on blood-thinning medications, such as Coumadin(R) (warfarin). The reporting and device management capabilities of RALS-Plus can also help hospital staff streamline the regulatory compliance process, capture reimbursable costs, and improve their organizational efficiency.

When the CoaguChek XS Plus System is docked in the optional Handheld Base Unit, it seamlessly transfers data to the RALS-Plus system through the hospital's information network. The bi-directional data transfer capability allows POC coordinators or other staff to configure individual meter settings from a central location. It also gives them convenient control and management of quality and safety features like operator lockout (to help ensure compliance with certification requirements) and quality control lockouts.

"With the growing influence of Pay for Performance and other quality-based initiatives in healthcare, hospitals are looking for data management solutions to help them reduce costs and improve patient care," said Brian Gunderson, Director of Product Portfolio Management at Medical Automation Systems, which developed the RALS system. "RALS-Plus is designed to do both."

The most significant benefits of connectivity with RALS-Plus relate to enhanced patient safety and quality control, according to Robert Hach, Point of Care Coordinator at Cleveland's MetroHealth System, which has been using RALS-Plus to manage its POC blood glucose testing program for five years and served as a test site for the CoaguChek XS Plus connectivity module. "During the beta test, the connectivity to RALS-Plus allowed us to control the PT/INR meters remotely, so we could manage operator certification and protocol compliance from one location," he says. "That took away any worries about an unauthorized person using the meter, and helped ensure the safety of our patients."

RALS-Plus helps hospitals address quality initiatives by giving them centralized control of point-of-care testing devices, including Roche's ACCU- CHEK(R) Inform system for blood glucose, according to Keith Snyder, Director of IT Marketing at Roche. "Now facilities that use the CoaguChek XS Plus System can extend the benefits of centralized data management to point-of-care testing in their warfarin clinics as well," he said.

The CoaguChek XS Plus System can store up to 500 patient and/or liquid quality control results that can be searched by patient ID, date, and time. It uses two-level, built-in quality controls to help ensure the accuracy of PT/INR test results, but also offers optional liquid quality controls for facilities with policies requiring the use of external quality control measures.

About Anticoagulation Monitoring

Patients with atrial fibrillation, a mechanical heart valve and other conditions often require protection against thrombosis, or blood clots. They are typically put on lifelong oral anticoagulation therapy with Coumadin (warfarin) to thin their blood. Each patient reacts differently to anticoagulant medication, so it is imperative to monitor the therapeutic effects to keep potential risks at the lowest possible level.

About the CoaguChek family of products

Physicians have been using CoaguChek instruments for POC PT/INR (Prothrombin Time/International Normalized Ratio) testing since 1994. Today, in the U.S., more PT/INR tests at the point of care are done using a CoaguChek system than with all other devices combined.(1) The CoaguChek XS Plus System represents the fifth generation of point-of-care anticoagulation monitoring devices from Roche Diagnostics.

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis, and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders, and diseases of the central nervous system. In 2007, sales by the Pharmaceuticals Division totaled 36.8 billion Swiss francs, and the Diagnostics Division posted sales of 9.3 billion francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai, and invested more than 8 billion Swiss francs in R&D in 2007. Worldwide, the Group employs about 79,000 people. Additional information is available on the Internet at

About MAS and RALS-Plus

Medical Automation Systems is recognized as the leader in information management for point-of-care testing. For years, the name RALS has been synonymous with point-of-care information management and widely recognized as the leading connectivity system available on the market. Today, more than 1,300 hospitals throughout the country manage their programs with RALS.

All trademarks used or mentioned in this release are protected by law.

CoaguChek is a trademark of Roche. RALS is a trademark of Medical Automation Systems. Coumadin is a trademark of Bristol-Myers Squibb Pharma Company.

(1) 4th quarter 2007 total market share of projected distributor unit sales of the Point of Care Testing Coagulation Reagents and Kits product class by HPIS Market Intelligence, a division of the GHX Global Healthcare Exchange.

For further information please contact:

Wendy Baker-Stein

Corporate Communications

Roche Diagnostics Corporation

Indianapolis, Ind.

Phone: 317-521-2745

SOURCE Roche Diagnostics
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Abbott Broadens Use of i-STAT Handheld Blood Analyzer with CLIA Waiver Granted by FDA for CHEM8+ Test Cartridge
2. Aribex Unveils New Handheld Intraoral X-ray System - NOMAD Pro
3. Handheld DNA detector
4. Different method of evaluating the urinary tract system reduces radiation dose
5. Lutheran Senior Services Partners with Silverchair Learning Systems to Enhance Employee Training and Education
6. Exempla Healthcare Contracts For Talismans Quality Donor System
7. Heartline(R) Fitness Systems Named to Inc. Magazines Inaugural List of the 5000 Fastest Growing Private Companies in U.S....
8. University of Wisconsin Hospitals and Clinics Complete System-Wide Conversion to Masimo SET Pulse Oximetry Technology
9. Plexus Systems Ranks in Top Third of the 2007 Inc. 5,000 with Three-Year Sales Growth of 226%
10. Document Security Systems (Amex: DMC) Invites You to a Landmark Event
11. Flu Vaccinations Begin on September 29 Maxim Health Systems to Provide 24,000 Flu Shot Clinics Nationwide
Post Your Comments:
(Date:11/30/2015)... , ... November 30, 2015 , ... ... continuing education course in Dallas, TX, on January 29 and 30, 2016. The ... improve the functions of their practices, to learn how to better succeed in ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... a key disease-causing component of bacteria could be effective in fighting methicillin-resistant Staphylococcus ... Georgia State University. , Their study showed that small molecule analogs that target ...
(Date:11/30/2015)... ... November 30, 2015 , ... Dr. Seth D. Margulies ... locations, patients can visit Dr. Margulies to experience the best available orthodontic experience in ... title of "NJ Top Dentist"! , Orthodontics is the branch of dentistry that specializes ...
(Date:11/30/2015)... ... 2015 , ... ”Dying Words: The AIDS Reporting of Jeff Schmalz and How ... coincide with World AIDS Day. The multi-media project will be in audio documentary form ... he was dying of the disease. , A collaborative effort led by author, professor ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... Reports magazine, quoted Michael Hansen, Ph.D., a senior scientist at Consumer Reports as ... more so for a child’s exposure limits. , The original Nov 2015 CR ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... KONG, Nov. 30, 2015 (HK$,000)For the Six Months Ended 30 September 2015 ... Income , 421,979 , 384,242 , ... , 34,719 , (18.3) Medical Insurance ... , 16.1 Medical Devices and Accessories Sales , ... Chinese Herbal Medicines Sales , 2,822 , ...
(Date:11/30/2015)... Calif. , Nov. 30, 2015 /PRNewswire/ ... the norm in U.S. medical imaging is ... increasingly popular accountable care payer-provider contracts are ... and, in their wake, alter provider-vendor relationships. ... payments will push forward new purchasing frameworks ...
(Date:11/30/2015)... Nov. 30, 2015 Oramed Pharmaceuticals Inc. (NASDAQ: ... the development of oral drug delivery systems, announced today ... at up to $50,000,000 with Hefei Tianhui Incubator of Technologies Co., Ltd. ... capsule, ORMD-0801, in China , ... . The agreements were signed at the Israel ...
Breaking Medicine Technology: